Now live: Innocentive Marketplace. Get shortlisted for funded opportunities today.

Novel Disease Indications for AstraZeneca Clinical Compounds

73 Submissions
$15,000 USD
Challenge closed

Challenge overview

Pharmaceutical R&D faces a number of significant challenges including budget limitations, lengthy development times and a high rate of attrition in drug discovery and development. These challenges restrict companies from pursuing many indications for clinical drug candidates, and potentially mean that important discoveries are not made.

To address these limitations, AstraZeneca is seeking novel clinical indications for a select set of compounds previously in clinical development.  These “patient-ready” compounds, with evidence of human target coverage and manageable tolerability, are available for novel clinical indications- preferably in diseases with significant unmet medical need.  These compounds provide valuable opportunities to explore disease biology, advance medical science, and potentially discover a new therapy for patients.

This Challenge requires only a written proposal.

AstraZeneca’s ultimate mission is to make a difference through medicines for patients, their families, stakeholders, and society in general.  Scientific research is the key to achieving this, in collaboration with others. Within the overall AstraZeneca strategy, cutting-edge innovation is at the heart of what we do, and the R&D strategy has been carefully constructed to deliver on the promise to patients, customers, and shareholders.

AstraZeneca is seeking novel clinical indications for a select set of compounds previously in clinical development.  A number of “patient-ready” compounds with evidence of human target coverage and manageable tolerability, collated in the  Compound Table (found in the Detailed Description of this challenge) are available for novel clinical indications, preferably in diseases with significant unmet medical need. These compounds provide valuable opportunities to explore disease biology, advance medical science, and potentially discover a new therapy for patients.

This is a Theoretical Challenge that requires only a written proposal to be submitted.  The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

To receive the full award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.  The Seeker, at their sole discretion, may opt for a licensing agreement for a partial award of $10,000 if exclusive IP is not required by the Seeker, or cannot be transferred by the Solver.

Use the slider to explore how the Challenge process works:

Register

Review & Accept

Submit

Win

To start solving this Challenge, log in to the Challenge Center or register as a Solver